Susan Krumplitsch

Partner, DLA Piper

Silicon Valley, United States

About me

Susan Krumplitsch represents life science companies in intellectual property disputes, with an emphasis on Hatch-Waxman, BPCIA and trade secret litigation. Her clients include innovative biotechnology, pharmaceutical and medical device companies and she regularly appears in federal courts across the country and in post-grant review proceedings at the US Patent and Trademark Office.

Her practice involves a wide variety of technologies, including therapeutic monoclonal antibodies, pharmaceutical formulations, small molecule drug compounds, next-generation DNA sequencing, mammalian cell lines, biofuels, fungicides and magnetic resonance angiography. Susan's trial experience includes bench and jury trials in federal courts, oral arguments at the Patent Trial and Appeal Board (PTAB), hearings before the International Trade Commission and domestic arbitrations.

She also has significant pro bono experience representing asylum applicants and drafting amicus briefs for various US Circuit Courts of Appeal and the Supreme Court of the United States.

07 Apr 2021

Patent eligibility in bioinformatics: Federal Circuit affirms rejection of computerized haplotype phasing claims

By Aaron Bowling, John McDermott, Susan Krumplitsch

In a pair of opinions issued in March, the Federal Circuit affirmed two Patent Trial and Appeal Board determinations that...